Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CET

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to nymonitoring@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01/14 JOHNSON & JOHNSON : Dancing with Abilene Stars raises $446,000
01/13 JOHNSON & JOHNSON : Ask The Doctors
01/13 JOHNSON & JOHNSON : Evidence not conclusive about talc Ask the Doctors
01/13 ROCHE : Johnson & Johnson and Alstrom Syndrome UK Address Hot Topic of Paediatri..
01/12 JOHNSON & JOHNSON : Study Findings from Johnson & Johnson Broaden Understanding ..
01/12 JOHNSON & JOHNSON : Missouri Court Denies J&J Request to Delay Talc-Related Canc..
01/12 JOHNSON & JOHNSON : Innovation's Global Pursuit of Cutting-Edge Science Yields 1..
01/11 CORRECTION : Drug Prices-Johnson & Johnson story
01/11 JOHNSON & JOHNSON : Innovation, New York State and New York Genome Center Collab..
01/11 JOHNSON & JOHNSON : - Dr. Paul Janssen Award for Biomedical Research Issues 2017..
More news
Sector news : Pharmaceuticals - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/13DJLONDON MARKETS : FTSE 100 Continues Record Run, Rising For 14th Day In A Row
01/13 FTSE hits record highs, extends historic winning streak
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12 Investors in big pharma, biotech look to ride out Trump storm
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01:44a Johnson & Johnson Goes Up Against Verizon In The Conference Finals
01/14 MONTHLY REVIEW OF DIVGRO : December 2016
01/13 RAYTHEON : Great Total Return Plus Dividend Hike In March
01/13 Johnson & Johnson - Actelion deal to be valued at $250 - 260, including R&D s..
01/12 The 10 Most Popular Dividend Growth Stocks Of Dividend Growth Bloggers
Advertisement
Financials ($)
Sales 2016 72 041 M
EBIT 2016 21 881 M
Net income 2016 16 368 M
Finance 2016 17 252 M
Yield 2016 2,74%
P/E ratio 2016 19,41
P/E ratio 2017 17,13
EV / Sales 2016 4,09x
EV / Sales 2017 3,83x
Capitalization 311 773 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 125 $
Spread / Average Target 9,2%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.53%311 773
ROCHE HOLDING LTD.2.75%204 641
PFIZER INC.0.12%197 343
NOVARTIS AG-1.48%189 749
MERCK & CO., INC.5.89%171 880
SANOFI1.52%107 323
More Results